Freeze-all indications in women with subfertility undergoing IVF: a cohort study.

V��ronique Moens, Juan Fontes Jim��nez, Marcos Ferrando Serrano, Daniel Ord����ez P��rez, Elkin Mu��oz, Claudio ��lvarez Pinochet, Manuel Fern��ndez-S��nchez, Alberto Reche Rosado, Margarita Torres Vives, Elisabet Aug��, Alejandro Dom��nech, Juan Antonio Garc��a-Velasco, Freeze-all Group
Author Information
  1. V��ronique Moens: Cl��nica Fertilab, Barcelona, Spain.
  2. Juan Fontes Jim��nez: Instituto Avantia de Fertilidad, Granada, Spain.
  3. Marcos Ferrando Serrano: IVIRMA Bilbao, Lejona, Spain.
  4. Daniel Ord����ez P��rez: Hospital Ruber Juan Bravo. Grupo EUGIN, Madrid, Spain.
  5. Elkin Mu��oz: IVIRMA Vigo, Vigo, Spain.; Department of Obstetrics and Gynaecology, University of Cauca, Popayan, Colombia.
  6. Claudio ��lvarez Pinochet: Centro Gutenberg, M��laga, Spain.
  7. Manuel Fern��ndez-S��nchez: Vida Sevilla Recoletas Sevilla, Sevilla, Spain.; Department of Surgery, University of Sevilla, Sevilla, Spain.
  8. Alberto Reche Rosado: Hospital Regional Universitario de M��laga, M��laga, Spain.
  9. Margarita Torres Vives: IVIRMA Mallorca, Mallorca, Spain.
  10. Elisabet Aug��: Scientific Office, Gedeon Richter Ib��rica, Barcelona, Spain.. Electronic address: augee@gedeonrichter.com.
  11. Alejandro Dom��nech: Scientific Office, Gedeon Richter Ib��rica, Barcelona, Spain.
  12. Juan Antonio Garc��a-Velasco: IVIRMA Madrid, Madrid, Spain.. Electronic address: Juan.Garcia.Velasco@ivirma.com.

Abstract

RESEARCH QUESTION: How widely is the freeze-all strategy implemented in clinical practice, and what are its indications?
DESIGN: This multicentre, prospective observational study included women aged ���18 years with subfertility and a clinical indication for IVF or intracytoplasmic sperm injection (ICSI) across 24 Spanish assisted reproductive treatment (ART) centres. Patients were included between February 2021 and July 2022, and followed-up until confirmation of pregnancy (ongoing pregnancy, ���20 weeks) or 6 months after cryopreservation. The primary endpoint was the proportion of patients who cryopreserved all available embryos and the main indications.
RESULTS: The population comprised 1034 evaluable women (mean �� SD age 36.3 �� 4.1 years). The main causes of subfertility were male factor (301/1034, 29.1%) and maternal age (277/1034, 26.8%). Ovarian stimulation with FSH plus highly purified urinary human menopausal gonadotrophin/LH was performed in 466/906 (51.4%) women. For pituitary down-regulation, most women (704/881, 79.9%) received the gonadotrophin-releasing hormone antagonist ganirelix. The freeze-all strategy was indicated in 794 (78.1%) patients, with the most common reasons being planned preimplantation genetic testing (490/794, 61.7%) and risk of ovarian hyperstimulation syndrome (192/794, 24.2%). Of the 709 first embryo transfers analysed, 132 (18.6%) were fresh embryo transfers and 577 (81.4%) were frozen embryo transfers. By the third embryo transfer, the cumulative rates of clinical and ongoing pregnancy per embryo transfer were 72.2% (436/604) and 62.9% (317/504), respectively.
CONCLUSIONS: The preferred treatment strategy in the study cohort was to freeze all available embryos, mainly because of planned preimplantation genetic testing and to avoid the risk of ovarian hyperstimulation syndrome.

Keywords

Word Cloud

Created with Highcharts 10.0.0womenembryostrategypregnancyclinicalstudysubfertilitytransferstransferfreeze-allincludedyearsIVF24treatmentongoingpatientsavailableembryosmainindications��age1%Ovarianstimulation4%9%plannedpreimplantationgenetictestingriskovarianhyperstimulationsyndrome2%cohortFreeze-allRESEARCHQUESTION:widelyimplementedpracticeindications?DESIGN:multicentreprospectiveobservationalaged���18indicationintracytoplasmicsperminjectionICSIacrossSpanishassistedreproductiveARTcentresPatientsFebruary2021July2022followed-upconfirmation���20weeks6monthscryopreservationprimaryendpointproportioncryopreservedRESULTS:populationcomprised1034evaluablemeanSD36341causesmalefactor301/103429maternal277/1034268%FSHplushighlypurifiedurinaryhumanmenopausalgonadotrophin/LHperformed466/90651pituitarydown-regulation704/88179receivedgonadotrophin-releasinghormoneantagonistganirelixindicated79478commonreasons490/794617%192/794709firstanalysed132186%fresh57781frozenthirdcumulativeratesper72436/60462317/504respectivelyCONCLUSIONS:preferredfreezemainlyavoidundergoingIVF:EmbryoOngoingrate

Similar Articles

Cited By